About AVT
Browse Articles
Authors
Customer Services

Current Issue

Displaying 11 results:

Case report

Bull’s eye maculopathy in an HIV-positive patient receiving ritonavir

Lemuel Non, Abdallah Jeroudi, Bradley T Smith, Shadi Parsaei

Antiviral Therapy 2016; 21:365-367


Short communication

Cerebrospinal fluid and plasma lopinavir concentrations and viral response in virologically suppressed patients switching to lopinavir/ritonavir monotherapy once daily

Juan M Tiraboschi, Hernando Knobel, Arkaitz Imaz, Judith Villar, Elena Ferrer, Maria Saumoy, Alicia González, Nerea Rozas, Antonia Vila, Jordi Niubó, Jordi Curto, Daniel Podzamczer

Antiviral Therapy 2016; 21:359-363


Short communication

Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand

The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC)† Study Group in EuroCoord

Antiviral Therapy 2016; 21:353-358


Original article

Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatment

Jordi Navarro, Estrella Caballero, Adrian Curran, Joaquin Burgos, Inma Ocaña, Vicenç Falcó, Ariadna Torrella, Mercè Pérez, Esteban Ribera, Manuel Crespo

Antiviral Therapy 2016; 21:345-352


Original article

Sustained immune control in HBeAg-positive patients who switched from entecavir therapy to pegylated interferon-α2a: 1 year follow-up of the OSST study

Meifang Han, Jiaji Jiang, Jinlin Hou, Deming Tan, Yongtao Sun, Mianzhi Zhao, Qin Ning

Antiviral Therapy 2016; 21:337-344


Original article

Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study

Sandrine Gazaignes, Matthieu Resche-Rigon, Caroline Gatey, Chloe Yang, Blandine Denis, Julien Fonsart, Kristell Desseaux, Michel Guionie, Willy Rozenbaum, Constance Delaugerre, Jean-Michel Molina

Antiviral Therapy 2016; 21:329-336


Original article

Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study

Lotke Tambuyzer, Kim Thys, Annemie Hoogstoel, Steven Nijs, Frank Tomaka, Magda Opsomer, Sandra De Meyer, Johan Vingerhoets

Antiviral Therapy 2016; 21:317-327


Original article

Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice

Hiromi Kan, Nobuhiko Hiraga, Michio Imamura, C Nelson Hayes, Takuro Uchida, Eisuke Miyaki, Masataka Tsuge, Hiromi Abe, Hiroshi Aikata, Daiki Miki, Hidenori Ochi, Yuji Ishida, Chise Tateno, Kazuaki Chayama

Antiviral Therapy 2016; 21:307-315


Original article

Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection

Laetitia Canini, Jeremie Guedj, Anushree Chatterjee, Annabelle Lemenuel-Diot, Patrick F Smith, Alan S Perelson

Antiviral Therapy 2016; 21:297-306


Original article

Effects on vitamin D, bone and the kidney of switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy: a randomized, controlled trial (MIDAS)

Lisa Hamzah, Juan M Tiraboschi, Helen Iveson, Martina Toby, Christine Mant, John Cason, Keith Burling, Emily Wandolo, Isabelle Jendrulek, Chris Taylor, Fowzia Ibrahim, Ranjababu Kulasegaram, Alastair Teague, Frank A Post, Julie Fox

Antiviral Therapy 2016; 21:287-296


Page:
Copyright © Nucleus Global 2016. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.